Christine Birdwell

机构：The University of Texas MD Anderson Cancer Center

发表论文 68 篇 · 总被引 921 次 · h-index 13

代表论文

• BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor (2024 · Blood · 被引 43)
• Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML (2024 · Blood · 被引 11)
• Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase (2025 · Blood Advances · 被引 4)
• Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM) (2024 · Blood Cancer Journal · 被引 4)
• BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML (2025 · Leukemia · 被引 3)
• Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations (2025 · Blood Cancer Journal · 被引 2)